Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MediVas signs eye disease agreement with Pfizer
By combining the fully biodegradable and biocompatible MediVas polymers with the Pfizer compounds, MediVas and Pfizer hope to create a product that can change the paradigm of how
By combining the fully biodegradable and biocompatible MediVas polymers with the Pfizer compounds, MediVas and Pfizer hope to create a product that can change the paradigm of how
Ribavirin is an anti-viral drug which is active against a number of DNA and RNA viruses. It is used in the treatment of influenzas, flaviviruses and agents of
Under the terms of the agreement, Foamix will receive certain development fees and milestone payments. Upon commercialization of the product, Foamix will receive royalty based on net sales.
The $2.4 million grant, which was awarded to a Crucell-led consortium of six leading European Universities and companies in the field of malaria research, will finance preclinical studies
“LX1031 may provide a useful treatment alternative for the management of patients suffering with IBS who are not well managed with existing therapies,” said Philip Brown, vice president
Until now, available therapies have only been able to slow the decline in vision, not to improve it. Lucentis is the first therapy shown in clinical trials to
The drug was tested in rheumatoid arthritis (RA) patients who had an inadequate response to methotrexate, a current standard of care. The study showed that a greater proportion
ReNeuron recently applied to the FDA to request trials of a controversial treatment using the stem cells of fetuses to treat stroke patients. The worldwide market for Parkinson's
The study will examine the safety, tolerability and effectiveness of oral cladribine combined with a new formulation of Rebif in multiple sclerosis patients with active disease despite treatment
The marketing application is for the use of Thalidomide Pharmion in untreated multiple myeloma patients. Thalidomide Pharmion has been designated as an orphan medicinal product in the EU.